Page last updated: 2024-08-23

epirubicin and Cancer of Prostate

epirubicin has been researched along with Cancer of Prostate in 70 studies

Research

Studies (70)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (10.00)	18.7374
1990's	31 (44.29)	18.2507
2000's	21 (30.00)	29.6817
2010's	8 (11.43)	24.3611
2020's	3 (4.29)	2.80

Authors

Authors	Studies
Cheng, K; Duan, F; Feng, DP; Fu, JX; Wang, MQ; Xin, H; Ye, HY; Yu, HK; Yuan, B; Zhang, JL; Zhang, XJ	1
Das, U; Gupta, S; Sinha, S	1
Adamczuk, G; Adamczuk, K; Dudka, J; Grabarska, A; Humeniuk, E	1
Abdeen, S; Alexander, P; Bhagat, M; Chavali, M; Praseetha, PK; Rose, PA	1
Abnous, K; Danesh, NM; Ramezani, M; Sarreshtehdar Emrani, A; Tabrizian, K; Taghdisi, SM; Zandkarimi, M	1
Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C	1
Ersoy, H; Kiper, A; Sagnak, L; Topaloglu, H; Yigitbasi, O	1
Fiaschi, AI; Francini, E; Francini, G; Pascucci, A; Petrioli, R	1
Crisci, A; Della Melina, A; Molinara, E; Neri, B; Nicitat, G; Pantaleo, P; Rangan, S; Raugei, A; Villari, D	1
Böhm, S; Brändle, M; Gillessen, S; Hess, D	1
Aigner, A; Czubayko, F; Frömberg, A; Gutsch, D; Schulze, D; Vollbracht, C; Weiss, G	1
Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R	1
Forsey, S; Harris, V; Lloyd, K; Parker, C; Roche, M; Rogers, P	1
Chen, ZD; Jiang, H; Wu, LJ; Xia, D	1
Correale, P; Fiaschi, AI; Francini, G; Manganelli, A; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Salvestrini, F	1
Köhn, FM; Meineke, V; Pickl, U; Ring, J; Vogt, HJ	1
Caris, CT; Carpentier, P; de Bruin, MJ; Debruyne, FM; Fernandez de Moral, P; van Andel, G; Wils, J; Witjes, JA; Witjes, WP	1
Brodak, M; Louda, M; Moravek, P; Odrazka, K; Petera, J; Prosvic, P; Rydel, L; Simakova, E; Vaculikova, M; Veselsky, Z; Zoul, Z	1
Habuchi, T; Kamoto, T; Nakashima, M; Nishiyama, H; Ogawa, O; Yagihashi, Y; Yamamoto, S	1
Canda, AE; Kirkali, Z; Mungan, MU; Tuzel, E; Yorukoglu, K	1
Birtle, AJ; Harland, SJ; Newby, JC	1
Bartoletti, R; Cipriani, G; Della Melina, A; Di Cello, V; Dominici, A; Fulignati, C; Maleci, D; Neri, B; Nicita, G; Ponchietti, R; Raugei, A; Turrini, M; Villari, D	1
Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R	1
Dolezal, J; Dolezel, M; Moravek, P; Odrazka, K; Petera, J; Prosvic, P; Simakova, E; Vaculikova, M; Vosmik, M; Zoul, Z	1
Budman, DR; Calabro, A	1
Francini, E; Francini, G; Manganelli, A; Paolelli, L; Petrioli, R; Salvestrini, F	1
Francini, E; Francini, G; Manganelli, A; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F	1
Csomor, J; Egyed, M; Egyházi, Z; Fekete, S; Kaszás, I; Kollár, B; Pajor, L; Timár, B	1
Brausi, M; de Mulder, PH; Droz, JP; Fosså, SD; Jones, WG; Lentz, MA; Pawinski, A; van Glabbeke, M	1
Fosså, SD; Paus, E	1
Aitini, E; Bajetta, E; Biganzoli, L; Bochicchio, AM; Buzzoni, R; Comella, G; D'Aprile, M; Di Leo, A; Nolè, F; Veltri, E	1
Anderström, C; Eddeland, A; Folmerz, P; Hansson, R; Milles, S; Zachrisson, B	1
Bichler, KH; Flüchter, SH; Strohmaier, WL; Wilbert, DM	1
Kanetake, H; Minami, Y; Saito, Y; Sakai, H	1
Anderström, C	1
Leliefeld, H; Peulen, G; Smeets, J; Wils, J	1
Erwin, TJ; Fontaine, B; Gupta, S; Stewart, DJ; Tannock, IF	1
Aquino, A; Cintorino, M; Francini, G; Manganelli, A; Marsili, S; Mondillo, S; Petrioli, R	1
Fujishiro, Y; Fuse, H; Katayama, T; Muraishi, Y	1
Foladore, S; Giuliotto, N; Merlo, A; Monfardini, S; Re, GL; Talamini, R; Veronesi, A	1
Chao, D; Harland, SJ	1
Alken, P; Köhrmann, KU; Kreukler, C; Siegsmund, MJ; Stendler, A	1
Fosså, SD; Heilo, A; Hernes, EH; Ogreid, P; Paus, E; Vaage, S	1
Boccardo, F; Canobbio, L; Esposito, M; Granetto, C; Miglietta, L; Vannozzi, MO	1
Hubmer, G; Lehnert, M; Pummer, K; Stettner, H	1
Chao, D; Harland, SJ; von Schlippe, M	1
Heidenreich, A	1
Denis, L	1
Abe, K; Asano, K; Kiyota, H; Ohishi, Y; Onodera, S	1
Allegrini, G; Antonuzzo, A; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Masi, G; Monica, L; Pfanner, E; Ricci, S	1
Aitken, SE; Huan, SD; Segal, R; Stewart, DJ; Yau, JC	1
Kurth, KH; Rietbroek, RL; van Andel, G; van De Velde-Muusers, JA	1
De Filippis, S; Pompili, PL; Rea, S; Recchia, F; Rosselli, M; Sica, G	1
Isogawa, Y; Kakehi, Y; Kamoto, T; Kinoshita, H; Mizutani, Y; Ogawa, O; Terachi, T; Wu, XX	1
Daniel, PT; Dörken, B; Gillissen, B; Graupner, V; Stärck, L; von Haefen, C; Wieder, T	1
Newling, DW	1
Delaere, KP; Leliefeld, H; Peulen, F; Smeets, J; Stapper, EW; Wils, J	1
Weissbach, L	1
Alfthan, O; Elomaa, I; Kellokumpu-Lehtinen, P; Rannikko, S	1
Akiyama, M; Sumiyoshi, Y; Yokota, K	1
Pummer, K	1
Hagen, S; Holme, I; Klepp, O; Kloster, SE; Muri, O; Poulsen, C; Sander, S; Sivertsen, S; Tveter, KJ; Urnes, T	1
Burk, K	1
Burk, K; Jonas, D; Rodeck, G; Schultze-Seemann, W	1
Papadopoulos, I; Wand, H	1
Dunzendorfer, U	1
Damber, JE; Landström, M; Tomić, R	1
Gröhn, P; Kontturi, M; Lukkarinen, O; Romppainen, ML; Sotarauta, M; Tammela, T	1
Burk, K; de Riese, W; Schultze-Seemann, W; Sropp, C	1
Bono, AV; De Pauw, M; Fosså, SD; Jones, WG; Klijn, JG; Sylvester, R	1

Reviews

5 review(s) available for epirubicin and Cancer of Prostate

Article	Year
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials. Actas urologicas espanolas, 2014, Volume: 38, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine	2014
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer treatment reviews, 2008, Volume: 34, Issue:8 Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome	2008
[A case report of a young patient with invasive bladder cancer]. Hinyokika kiyo. Acta urologica Japonica, 2003, Volume: 49, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Humans; Male; Methotrexate; Neoplasm Invasiveness; Prostatic Neoplasms; Urinary Bladder Neoplasms; Urinary Diversion	2003
Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer. Cancer chemotherapy and pharmacology, 1994, Volume: 35 Suppl Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Injections, Intramuscular; Male; Medroxyprogesterone Acetate; Orchiectomy; Prostatic Neoplasms; Survival Rate	1994
Weekly chemotherapeutic regimen in metastatic prostate cancer. Progress in clinical and biological research, 1990, Volume: 350 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Drug Administration Schedule; Drug Evaluation; Epirubicin; Germany, East; Humans; Male; Prostatic Neoplasms; Survival Rate	1990

Trials

35 trial(s) available for epirubicin and Cancer of Prostate

Article	Year
Comparison of three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer patients. TheScientificWorldJournal, 2008, Jun-13, Volume: 8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome	2008
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. British journal of cancer, 2011, Feb-15, Volume: 104, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure	2011
Weekly epirubicin in patients with hormone-resistant prostate cancer. British journal of cancer, 2002, Sep-23, Volume: 87, Issue:7 Topics: Aged; Androgens; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pain; Prostatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome	2002
A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World journal of urology, 2003, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Drug Administration Schedule; Epirubicin; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Quality of Life	2003
Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer. International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:7 Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dexamethasone; Drug Administration Schedule; Epirubicin; Etoposide; Hormone Antagonists; Humans; Male; Middle Aged; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome	2003
Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial. Anti-cancer drugs, 2005, Volume: 16, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome	2005
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. Journal of pain and symptom management, 2005, Volume: 29, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Epirubicin; Fluorouracil; Humans; Male; Mitomycin; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radiopharmaceuticals; Severity of Illness Index; Strontium; Treatment Outcome	2005
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology, 2007, Volume: 69, Issue:1 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Treatment Failure	2007
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:10 Topics: Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	1995
Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report. European urology, 1994, Volume: 26, Issue:1 Topics: Aged; Biomarkers, Tumor; Combined Modality Therapy; Epirubicin; Estramustine; Flutamide; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors	1994
Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group. American journal of clinical oncology, 1995, Volume: 18, Issue:3 Topics: Aged; Ambulatory Care; Bone Neoplasms; Drug Synergism; Drug Therapy, Combination; Epirubicin; Heart Failure; Humans; Male; Medroxyprogesterone Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Survival Analysis	1995
Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study. European urology, 1995, Volume: 27, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Estramustine; Heart Failure; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Prostatic Neoplasms; Recurrence	1995
Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. Cancer chemotherapy and pharmacology, 1994, Volume: 35 Suppl Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Epirubicin; Ethinyl Estradiol; Fluorouracil; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Survival Rate; Tegafur; Uracil	1994
Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer. Cancer chemotherapy and pharmacology, 1994, Volume: 35 Suppl Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Injections, Intramuscular; Male; Medroxyprogesterone Acetate; Orchiectomy; Prostatic Neoplasms; Survival Rate	1994
Phase II study of orchiectomy combined with epirubicin as first-line treatment in advanced prostate carcinoma. Cancer investigation, 1994, Volume: 12, Issue:4 Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Epirubicin; Follow-Up Studies; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Soft Tissue Neoplasms	1994
Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease. American journal of clinical oncology, 1993, Volume: 16, Issue:2 Topics: Aged; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms; Soft Tissue Neoplasms; Survival Analysis	1993
Weekly chemotherapy in advanced prostatic cancer. British journal of cancer, 1993, Volume: 67, Issue:6 Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Male; Middle Aged; Osteoblasts; Prostatic Neoplasms	1993
Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North-Eastern Italian Oncology Group (GOCCNE). European urology, 1996, Volume: 29, Issue:4 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Estramustine; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate; Time Factors; Treatment Outcome	1996
Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. British journal of cancer, 1997, Volume: 76, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Estramustine; Gastrointestinal Diseases; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Leukopenia; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Thrombocytopenia	1997
Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. Journal of cancer research and clinical oncology, 1997, Volume: 123, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; Male; Pilot Projects; Prostatic Neoplasms; Suramin	1997
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. European urology, 1997, Volume: 32 Suppl 3 Topics: Aged; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Flutamide; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Software; Treatment Outcome	1997
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Treatment Outcome	1997
[Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate]. Der Urologe. Ausg. A, 1997, Volume: 36, Issue:6 Topics: Analgesics, Non-Narcotic; Antibiotics, Antineoplastic; Bone Neoplasms; Clodronic Acid; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms	1997
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. Urology, 1998, Volume: 51, Issue:5A Suppl Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Castration; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Epirubicin; Estramustine; Flutamide; Humans; Imidazoles; Male; Medroxyprogesterone Acetate; Methotrexate; Mitomycin; Neoplasms, Hormone-Dependent; Procarbazine; Prostatic Neoplasms; Vindesine	1998
Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer, 1999, Aug-01, Volume: 86, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin	1999
Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. American journal of clinical oncology, 1999, Volume: 22, Issue:5 Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	1999
Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible? European urology, 2000, Volume: 38, Issue:3 Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Studies; Humans; Male; Medroxyprogesterone Acetate; Middle Aged; Prospective Studies; Prostatic Neoplasms; Quality of Life	2000
Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma. American journal of clinical oncology, 2001, Volume: 24, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Epirubicin; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate	2001
Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma. British journal of urology, 1992, Volume: 70, Issue:6 Topics: Aged; Alopecia; Bone Neoplasms; Drug Resistance; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms; Time Factors	1992
[Prospective randomized multicenter phase III study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate]. Der Urologe. Ausg. A, 1992, Volume: 31, Issue:1 Topics: Epirubicin; Estramustine; Humans; Male; Mitomycin; Prospective Studies; Prostatic Neoplasms	1992
Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. European urology, 1991, Volume: 19, Issue:1 Topics: Aged; Epirubicin; Estramustine; Humans; Male; Middle Aged; Palliative Care; Prospective Studies; Prostatic Neoplasms	1991
Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Epirubicin; Flutamide; Follow-Up Studies; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate	1991
A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Scandinavian journal of urology and nephrology, 1990, Volume: 24, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Therapy, Combination; Epirubicin; Estramustine; Humans; Injections, Intravenous; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Norway; Placebos; Prospective Studies; Prostatic Neoplasms; Remission Induction	1990
Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up. Progress in clinical and biological research, 1989, Volume: 303 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Epirubicin; Follow-Up Studies; Germany, West; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Neoplasms; Time Factors	1989
[Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study]. Onkologie, 1989, Volume: 12 Suppl 3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Erythrocyte Count; Hemoglobinometry; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Peptides; Platelet Count; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tissue Extracts; Vomiting	1989

Other Studies

31 other study(ies) available for epirubicin and Cancer of Prostate

Article	Year
Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer. Prostate cancer and prostatic diseases, 2023, Volume: 26, Issue:1 Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Docetaxel; Epirubicin; Hematuria; Humans; Liver Neoplasms; Male; Middle Aged; Prostate; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Urinary Retention	2023
IGT mediated Nanog siRNA delivery in prostate cancer cells improves chemosensitization of Epirubicin in vitro. Bioorganic & medicinal chemistry letters, 2022, 11-15, Volume: 76 Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Epirubicin; Guanidine; Humans; Male; Morpholinos; Nanog Homeobox Protein; Organic Cation Transport Proteins; Peptides; Prostatic Neoplasms; RNA, Small Interfering	2022
2,4-Dinitrophenol as an Uncoupler Augments the Anthracyclines Toxicity against Prostate Cancer Cells. Molecules (Basel, Switzerland), 2022, Oct-25, Volume: 27, Issue:21 Topics: 2,4-Dinitrophenol; Anthracyclines; Antibiotics, Antineoplastic; Dinitrophenols; Doxorubicin; Epirubicin; Humans; Male; Prostatic Neoplasms; Sulfhydryl Compounds	2022
Drug embedded PVP coated magnetic nanoparticles for targeted killing of breast cancer cells. Technology in cancer research & treatment, 2013, Volume: 12, Issue:5 Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Coated Materials, Biocompatible; Drug Delivery Systems; Epirubicin; Female; Folic Acid; Humans; Leukemia; Lung Neoplasms; Magnetite Nanoparticles; Male; Pharmaceutic Aids; Povidone; Prostatic Neoplasms; Spectroscopy, Fourier Transform Infrared	2013
Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. Journal of drug targeting, 2013, Volume: 21, Issue:8 Topics: Antigens, Neoplasm; Antineoplastic Agents; Aptamers, Nucleotide; Benzeneacetamides; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Epirubicin; Humans; Male; Piperidones; Polyethylene Glycols; Prostatic Neoplasms	2013
Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma. Oncology research, 2009, Volume: 17, Issue:11-12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Humans; Male; Prostatic Neoplasms; Taxoids	2009
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Diabetes care, 2010, Volume: 33, Issue:6 Topics: Aged; Antibiotics, Antineoplastic; Blood Glucose; Diabetes Mellitus, Type 2; Epirubicin; Humans; Hypoglycemic Agents; Indazoles; Male; Prostatic Neoplasms; Pyrimidines; Sulfonamides	2010
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dehydroascorbic Acid; Docetaxel; Drug Synergism; Epirubicin; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine	2011
A population-based study of prostate cancer chemotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)), 2011, Volume: 23, Issue:10 Topics: Antineoplastic Agents; Docetaxel; Drug Therapy; Epirubicin; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Taxoids; United Kingdom	2011
Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells. Chinese medical journal, 2011, Volume: 124, Issue:23 Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epirubicin; Flow Cytometry; Humans; Male; Oligonucleotides, Antisense; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction	2011
[Malignant priapism as a sign of a recurrent prostate cancer. Differential diagnosis of induratio penis plastica]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:6 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Diagnosis, Differential; Drug Therapy, Combination; Epirubicin; Estramustine; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Orchiectomy; Palliative Care; Penile Induration; Penile Neoplasms; Priapism; Prostatic Neoplasms; Time Factors	2003
Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder. European urology, 2004, Volume: 45, Issue:4 Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Epirubicin; Follow-Up Studies; Humans; Male; Middle Aged; Mucous Membrane; Neoplasms, Multiple Primary; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms	2004
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Epirubicin; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Survival Rate	2004
Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer? Oncology reports, 2005, Volume: 14, Issue:4 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hormones; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Thrombocytopenia; Time Factors; Treatment Outcome	2005
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology, 2006, Volume: 70, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid	2006
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:2 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Care; Preoperative Care; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Risk Assessment; Survival Rate; Treatment Outcome	2008
Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma. Pathology oncology research : POR, 2008, Volume: 14, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Lymphoma, B-Cell; Male; Prostatectomy; Prostatic Neoplasms; Rituximab; Survival	2008
Influence of transrectal hyperthermia on prostate-specific antigen in prostatic cancer and benign prostatic hyperplasia. Urologia internationalis, 1993, Volume: 51, Issue:1 Topics: Aged; Combined Modality Therapy; Epirubicin; Flutamide; Humans; Hyperthermia, Induced; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Radiotherapy, High-Energy; Time Factors	1993
Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer. International urology and nephrology, 1996, Volume: 28, Issue:1 Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Castration; Drug Resistance; Epirubicin; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate	1996
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. European urology, 1997, Volume: 31, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diethylstilbestrol; Disease Progression; Epirubicin; Fluorouracil; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms	1997
Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. European urology, 1997, Volume: 31, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Division; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Idarubicin; KB Cells; Lethal Dose 50; Male; Prostatic Neoplasms; Rats; Tumor Cells, Cultured	1997
[A case of primary transitional cell carcinoma of the prostate responsive to combination chemotherapy with methotrexate, epirubicin and cisplatin]. Hinyokika kiyo. Acta urologica Japonica, 1998, Volume: 44, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Epirubicin; Humans; Male; Methotrexate; Prostatic Neoplasms; Remission Induction	1998
Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. International journal of oncology, 2002, Volume: 20, Issue:5 Topics: Acridine Orange; Anthracyclines; Antibiotics, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspase 6; Caspase 8; Caspase 9; Caspases; Coloring Agents; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Humans; Immunohistochemistry; Male; Membrane Glycoproteins; Prostatic Neoplasms; Recombinant Proteins; Tetrazolium Salts; Thiazoles; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2002
Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene, 2002, Jun-06, Volume: 21, Issue:25 Topics: Amino Acid Chloromethyl Ketones; Antibiotics, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase Inhibitors; Caspases; Cell Fractionation; Ceramides; Cysteine Proteinase Inhibitors; Cytochrome c Group; Epirubicin; Flow Cytometry; Humans; Male; Mitochondria; Oligopeptides; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retroviridae; Signal Transduction; Transfection; Tumor Cells, Cultured	2002
The use of adriamycin and its derivatives in the treatment of prostatic cancer. Cancer chemotherapy and pharmacology, 1992, Volume: 30 Suppl Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cellular Senescence; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms	1992
[Intra-arterial infusion chemotherapy for advanced bladder cancer and prostate cancer using reservoir system]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Infusion Pumps; Infusions, Intra-Arterial; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Urinary Bladder Neoplasms	1991
Hormonal chemotherapy. Progress in clinical and biological research, 1989, Volume: 303 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diethylstilbestrol; Epirubicin; Humans; Ifosfamide; Male; Orchiectomy; Prostatic Neoplasms	1989
Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma. European urology, 1987, Volume: 13, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Doxorubicin; Epirubicin; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasm Transplantation; Orchiectomy; Prostatic Neoplasms; Rats; Testosterone	1987
Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer. European urology, 1988, Volume: 15, Issue:1-2 Topics: Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Drug Administration Schedule; Drug Evaluation; Epirubicin; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prostatic Neoplasms	1988
Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly. Progress in clinical and biological research, 1987, Volume: 243B Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Fluorouracil; Humans; Male; Mitomycin; Mitomycins; Prostatic Neoplasms	1987
European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer treatment reports, 1987, Volume: 71, Issue:12 Topics: Aged; Carcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms	1987